Continue advancement of MRT-6160 through Phase 2 initiation, in collaboration with Novartis. Share additional MRT-2359 Phase 1/2 study data in CRPC patients resistant to AR therapy in H2 2025. Submit an IND application for MRT-8102 in H1 2025. Submit an IND application for the second generation NEK7-directed MGD with enhanced CNS penetration in 2026. Submit an IND application for a CDK2 and/or cyclin E1-directed MGD in 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE: